title: Fanconi anemia pathway defects in inherited and sporadic cancers.
abstract: Fanconi anemia (FA) is a recessive chromosomal instability syndrome. It is a hereditary disorder with defects in DNA repair characterized by progressive bone marrow failure, variable congenital malformations and predisposition to develop hematological or solid tumors. Bi-allelic gene mutations in FA cause not only the FA phenotype but also genome instability and additional mutations in their somatic cells resulting in a high predisposition to many different types of cancers. Mono-allelic mutation in FA genes increases the susceptibility to several types of cancers in a sporadic manner in non-FA patients. The strong link between cancer from bi-allelic and mono-allelic FA gene mutations has been well established. Studies have demonstrated a link between FA and cancer due to gene defects which cause the disruption of the FA pathways in a proportion of familial and sporadic cancers. The convincing evidence is that one of the FA genes, FANCD1 is identical to the well-known breast cancer susceptibility gene, BRCA2. Another three FA genes were found to be associated with genes mutated from breast cancer and other types of cancers such as prostate cancer as well. Studies on FA's biological function in genome instability maintenance, DNA damage/repair and its complex regulation pathways have become the main focus within the genetic cancer research field because of many unique features of FA. The lessons learnt from FA studies provided invaluable information towards the understanding of cancer pathogenesis to be translated into targeting cancer therapies. Studies also demonstrated that FA is a paradigm of cancer-prone inherited monogenic disease, offering insights into the pathogenesis of many types of human diseases, particularly in bone marrow failure, cancer and aging. In this review, brief FA clinical characteristics, identification of FA genes and their protein pathways, the pathogenic linking between cancers from bi-allelic and mono-allelic mutated FA genes will be discussed.
authors.affiliation: 1 Department of Internal Medicine, The First Hospital of Qiqihaer, Qiqihaer 161005, China ; 2 Department of Neonatology, Qiqihaer Hospital of the Traditional Chinese Medicine, Qiqihaer 161000, China ; 3 Western Sydney Genomic Diagnostics, Western Sydney Genetics Program, The Children's Hospital at Westmead, 2145, NSW, Australia.
authors.forename: Hong
authors.initials: H
authors.lastname: Chen
authors.affiliation: 1 Department of Internal Medicine, The First Hospital of Qiqihaer, Qiqihaer 161005, China ; 2 Department of Neonatology, Qiqihaer Hospital of the Traditional Chinese Medicine, Qiqihaer 161000, China ; 3 Western Sydney Genomic Diagnostics, Western Sydney Genetics Program, The Children's Hospital at Westmead, 2145, NSW, Australia.
authors.forename: Shuxia
authors.initials: S
authors.lastname: Zhang
authors.affiliation: 1 Department of Internal Medicine, The First Hospital of Qiqihaer, Qiqihaer 161005, China ; 2 Department of Neonatology, Qiqihaer Hospital of the Traditional Chinese Medicine, Qiqihaer 161000, China ; 3 Western Sydney Genomic Diagnostics, Western Sydney Genetics Program, The Children's Hospital at Westmead, 2145, NSW, Australia.
authors.forename: Zhanhe
authors.initials: Z
authors.lastname: Wu
keywords: Fanconi anemia (FA) pathway defects; genome instability; inherited and sporadic cancer susceptibility
references.citation: Anemia. 2012;2012:926787
references.pmid: 22675617
references.citation: Blood. 2006 Jun 1;107(11):4223-33
references.pmid: 16493006
references.citation: Proc Natl Acad Sci U S A. 2001 May 8;98(10):5734-9
references.pmid: 11344308
references.citation: Nat Genet. 2010 May;42(5):406-9
references.pmid: 20400963
references.citation: Nat Genet. 2010 May;42(5):410-4
references.pmid: 20400964
references.citation: Blood. 2002 Dec 15;100(13):4649-54
references.pmid: 12393398
references.citation: Expert Rev Anticancer Ther. 2006 Aug;6(8):1205-14
references.pmid: 16925486
references.citation: Cancer Res. 2003 May 15;63(10):2585-8
references.pmid: 12750283
references.citation: Mol Cell. 2001 Feb;7(2):249-62
references.pmid: 11239454
references.citation: Annu Rev Genet. 2009;43:223-49
references.pmid: 19686080
references.citation: Br J Haematol. 2003 Nov;123(3):469-71
references.pmid: 14617007
references.citation: Cancer. 2003 Jan 15;97(2):425-40
references.pmid: 12518367
references.citation: Blood. 2002 Oct 1;100(7):2414-20
references.pmid: 12239151
references.citation: Semin Hematol. 1967 Jul;4(3):233-40
references.pmid: 6074578
references.citation: Haematologica. 2008 Apr;93(4):511-7
references.pmid: 18322251
references.citation: Science. 2002 Jul 26;297(5581):606-9
references.pmid: 12065746
references.citation: Nat Struct Mol Biol. 2008 Nov;15(11):1128-30
references.pmid: 18985065
references.citation: J Med Genet. 2011 Apr;48(4):242-50
references.pmid: 21217111
references.citation: Mol Cell Biol. 2007 Dec;27(24):8421-30
references.pmid: 17938197
references.citation: Mol Cell Biol. 2000 Nov;20(21):8283-9
references.pmid: 11027296
references.citation: J Biol Chem. 2011 Sep 16;286(37):32628-37
references.pmid: 21775430
references.citation: Nat Genet. 1992 Jun;1(3):196-8
references.pmid: 1303234
references.citation: Blood. 2003 Feb 15;101(4):1249-56
references.pmid: 12393516
references.citation: Hum Mutat. 2013 Dec;34(12):1615-8
references.pmid: 24027083
references.citation: Hered Cancer Clin Pract. 2013 Sep 11;11(1):12
references.pmid: 24025454
references.citation: Nat Genet. 2010 May;42(5):368-9
references.pmid: 20428093
references.citation: Transl Res. 2012 Sep;160(3):178-97
references.pmid: 22683426
references.citation: Curr Biol. 2009 Mar 24;19(6):524-9
references.pmid: 19268590
references.citation: Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60
references.pmid: 19369211